Genesio Di Muro

Milan, 20122, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

IGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis.

IGF2R: a new player in the IGF2 loop sustaining adrenocortical carcinogenesis.

Journal: Cell communication and signaling : CCS

Published: February 18, 2026

Characterization of SF3B1 role in prolactin-secreting pituitary tumors.

Characterization of SF3B1 role in prolactin-secreting pituitary tumors.

Journal: Endocrine-related cancer

Published: December 15, 2025

Biological targets and therapeutic strategies in the treatment of non-functioning pituitary tumors: state-of-the-art.

Biological targets and therapeutic strategies in the treatment of non-functioning pituitary tumors: state-of-the-art.

Journal: European journal of endocrinology

Published: December 02, 2025

Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma.

Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma.

Journal: Pharmacological research

Published: August 07, 2025

Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells.

Potential antitumoral effects of SRPK1 inhibition through modulation of VEGF splicing in pituitary somatotroph tumoral cells.

Journal: Frontiers in endocrinology

Published: July 16, 2025

The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.

The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells.

Journal: International journal of molecular sciences

Published: February 08, 2024

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells.

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells.

Journal: Cancers

Published: April 17, 2023

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.

Journal: Cancers

Published: March 22, 2022

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5 homo- and hetero-dimer formation.

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5 homo- and hetero-dimer formation.

Journal: Frontiers in endocrinology

Published: March 17, 2022

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells.

Journal: Frontiers in endocrinology

Published: February 01, 2022

TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection.

TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection.

Journal: Frontiers in endocrinology

Published: January 26, 2022

USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.

USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.

Journal: Endocrine-related cancer

Published: May 28, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026